Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2009
12/30/2009WO2009156860A2 Substituted triazinone derivatives
12/30/2009WO2009156853A2 Compounds, compositions, and methods useful for modulating the expression of histone deacetylase (hdac) gene expression and/or activity
12/30/2009WO2009156706A1 Pulmonary drug delivery with vesicles comprising non-ionic surfactants
12/30/2009WO2009156421A1 Squaric acid derivatives as inhibitors of the nicotinamide
12/30/2009WO2009156315A1 Pyrazolo-quinazolines
12/30/2009WO2009156179A1 Her3 as a determinant for the prognosis of melanoma
12/30/2009WO2009155842A1 Fusion protein of onconase and toxin transmembrane domain and preparation method and use thereof
12/30/2009WO2009155742A1 Dextran for treating lung cancer
12/30/2009WO2009155709A1 Bridged secondary amines and use thereof as iap bir domain binding compounds
12/30/2009WO2009155659A1 Combination therapy
12/30/2009WO2009136995A3 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
12/30/2009WO2009127072A8 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
12/30/2009WO2009117831A9 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
12/30/2009WO2009114547A3 Enhanced dendritic cells for cancer immunotherapy
12/30/2009WO2009111277A9 Imidazo [4. 5-b] pyridine derivatives used as raf inhibitors
12/30/2009WO2009109866A3 Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3- (4-pyridin-3-yl-pyrimidin-2ylamino)-phenyl]-benzamide
12/30/2009WO2009106748A3 Derivatives of n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
12/30/2009WO2009106708A3 Azetidine derivatives, their preparation and their application in therapy
12/30/2009WO2009073546A3 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
12/30/2009WO2009065910A3 Acid addition salts of imatinib and formulations comprising the same
12/30/2009WO2009002425A3 Solubilized formulation of docetaxel without tween 80
12/30/2009WO2008138327A9 Polymerase inhibitors and the use thereof for the treatment of tumors
12/30/2009EP2138576A1 Anti-claudin-4 antibody
12/30/2009EP2138511A1 HER3 as a determinant for the prognosis of melanoma
12/30/2009EP2138498A1 Substituted tricyclic derivatives against neurodegenerative diseases
12/30/2009EP2138496A1 Antitumoral analogs of lamellarins
12/30/2009EP2138488A1 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
12/30/2009EP2138482A1 Bicyclic heterocyclic compound
12/30/2009EP2138180A1 A composition for treating cancer containing a porous silicon nanobomb as an active ingredient
12/30/2009EP2138179A1 Use of cytidine derivatives for the treatment of leukaemia
12/30/2009EP2138164A1 Liquid pharmaceutical formulations of docetaxel
12/30/2009EP2137536A1 Methods and compositions for inducing apoptosis by stimulating er stress
12/30/2009EP2137216A2 Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
12/30/2009EP2137213A1 Methods and compositions for treating prostate cancer
12/30/2009EP2137203A1 Ethynylated heterodinucleoside phosphate analogs, method for the production thereof, and use thereof
12/30/2009EP2137202A1 Process for the synthesis of ib-meca
12/30/2009EP2137186A1 Heterocyclic compounds and their uses
12/30/2009EP2137184A1 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
12/30/2009EP2137177A2 Aurora kinase modulators and method of use
12/30/2009EP2137166A1 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
12/30/2009EP2137155A1 Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases
12/30/2009EP2137150A1 Piperidinones useful in the treatment of inflammation
12/30/2009EP2137147A1 Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
12/30/2009EP2136843A1 Biomarkers of prostate cancer and uses thereof
12/30/2009EP2136840A2 Use of an anti-cxcr4 antibody for treating cancer
12/30/2009EP2136838A2 Epha3 antibodies for the treatment of solid tumors
12/30/2009EP2136832A1 Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
12/30/2009EP2136820A1 A target for breast cancer therapy and/or diagnosis
12/30/2009EP2136816A2 Oleyl phosphocholine
12/30/2009EP2136803A1 Triazole derivatives which are smo antagonists
12/30/2009EP2136788A1 Cancer cell targeting using nanoparticles
12/30/2009EP2136635A1 Chemical compounds
12/30/2009EP2136632A1 Chemical compounds
12/30/2009EP2004653B1 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors
12/30/2009EP2004625B1 C-met protein kinase inhibitors for the treatment of proliferative disorders
12/30/2009EP1904102B1 Anti-ccr7 receptor antibodies for the treatment of cancer
12/30/2009EP1848714B1 Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
12/30/2009EP1732902B1 Nucleoside derivatives and therapeutic use thereof
12/30/2009EP1727532B1 Chemically stable compositions of 4-hydroxy tamoxifen
12/30/2009EP1675864B1 Platinum complexes for the treatment of tumors
12/30/2009EP1664027B1 Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
12/30/2009EP1501812B1 Pna monomer and precursor
12/30/2009EP1487444B1 Use of pyridyl amides as inhibitors of angiogenesis
12/30/2009EP1470239B1 Psoriasin expression by breast epithelial cells
12/30/2009EP1430019B1 Sphingolipids
12/30/2009EP1409482B1 Dye-sulfenates for dual phototherapy
12/30/2009EP1202973B1 Preparation of compounds useful for the detection of hypoxia
12/30/2009CN201370888Y Multifunctional medicated pad
12/30/2009CN101613321A Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/30/2009CN100575482C Novel cytokine zcytor17 ligand
12/30/2009CN100575365C Loose knot total polysaccharide and preparation method and usage thereof
12/30/2009CN100575352C 1-(4- chloroanilino)-4-(4-methylpyridyl)-2,3-diazophenodiazine synthesis and uses
12/30/2009CN100575341C Tetrahydro-indolone derivative and tetrahydro-indazolone derivatives and their use
12/30/2009CN100574803C Use of immunoregulation antibody for the treatment of neoplastic disorders
12/30/2009CN100574780C Compositions against inflammatory processes
12/30/2009CN100574770C Slow releasing micro pill preparation of loosestrife extract and its preparation process
12/30/2009CN100574768C An anticancer medicinal composition, preparing method and use thereof
12/30/2009CN100574762C Portulaca total flavone injection and method for making same
12/30/2009CN100574760C Camptothecinum-layered thermometal hydroxide nanometer complexes preparation method
12/30/2009CN100574743C 抗老化剂 Anti-aging agents
12/30/2009CA2766328A1 New therapeutic agents
12/30/2009CA2729546A1 Compounds and compositions as kinase inhibitors
12/30/2009CA2729436A1 Pyrazolo-quinazolines
12/30/2009CA2729257A1 Schweinfurthin analogues
12/30/2009CA2729115A1 Substituted triazinone derivatives
12/30/2009CA2728960A1 Polymer-metal complex composite having mri contrast ability and mri contrasting and/or antitumor composition using the same
12/30/2009CA2728933A1 Bridged secondary amines and use thereof as iap bir domain binding compounds
12/30/2009CA2728851A1 Thiazolylpiperidine derivatives
12/30/2009CA2728806A1 Squaric acid derivatives as inhibitors of the nicotinamide phosphoribosyltransferase
12/30/2009CA2728728A1 Substituted tricyclic derivatives
12/30/2009CA2728674A1 Signatures and determinants associated with metastasis methods of use thereof
12/30/2009CA2728502A1 Liquid composition of cisplatin coordination compound
12/30/2009CA2727737A1 Materials and methods for suppressing and/or treating neurofibroma and related tumors
12/30/2009CA2727455A1 Heteroaryl compounds and uses thereof
12/30/2009CA2727340A1 Carboxylic acid compound
12/30/2009CA2714940A1 Her3 as a determinant for the prognosis of melanoma
12/29/2009USRE41065 Such as (6,7-dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine for treatment of hyperproliferative diseases
12/29/2009US7638627 Imatinib hydrochloride; reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidineamine with 4-(4-methyl-piperazinomethyl)benzoyl chloride; improved reduction step to simplify, increase yield, improve purity
12/29/2009US7638623 Galactoside inhibitors of galectins
12/29/2009US7638620 Use to enhance apoptosis; antiproliferative agents
1 ... 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 ... 2211